Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, Sheets M, St Martin T, Karp R, van Kalken D, Chaturvedi P, Niu D, Nacht M, Petter RC, Westlin W, Lin K, Jaw-Tsai S, Raponi M, Van Dyke T, Etter J, Weaver Z, Pao W, Singh J, Simmons AD, Harding TC, Allen A
Cancer Discov. 2013 3 (12): 1404-15

PMID: 24065731 · PMCID: PMC4048995 · DOI:10.1158/2159-8290.CD-13-0314

UNLABELLED - Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors. However, clinical efficacy is limited by acquired resistance, frequently driven by the EGFR(T790M) mutation. CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor. Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models. Minimal activity of CO-1686 against the WT EGFR receptor was observed. In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of additional mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors. These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.

SIGNIFICANCE - We report the preclinical development of a novel covalent inhibitor, CO-1686, that irreversibly and selectively inhibits mutant EGFR, in particular the T790M drug-resistance mutation, in NSCLC models. CO-1686 is the fi rst drug of its class in clinical development for the treatment of T790M-positive NSCLC, potentially offering potent inhibition of mutant EGFR while avoiding the on-target toxicity observed with inhibition of the WT EGFR.

©2013 AACR.

MeSH Terms (24)

Acrylamides Administration, Oral Animals Antineoplastic Agents Carcinoma, Non-Small-Cell Lung Cell Line, Tumor Cell Proliferation Drug Resistance, Neoplasm Drug Screening Assays, Antitumor Epithelial-Mesenchymal Transition ErbB Receptors Female HEK293 Cells Humans Lung Neoplasms Mice Mice, Inbred BALB C Mice, Nude Mice, Transgenic Molecular Targeted Therapy Mutant Proteins Protein Kinase Inhibitors Pyrimidines Xenograft Model Antitumor Assays

Connections (1)

This publication is referenced by other Labnodes entities: